NCT02643147View on ClinicalTrials.gov

Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)

PHASE4CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 30, 2017

Study Completion Date

January 30, 2017

Conditions
Heart Failure
Interventions
DRUG

CA125 guided strategy

Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.

DRUG

CA125 guided strategy

Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.

DRUG

Conventional Strategy

The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations

Trial Locations (1)

46010

Hospital Clínico Universitario de Valencia, Valencia

All Listed Sponsors
lead

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

NCT02643147 - Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF) | Biotech Hunter | Biotech Hunter